SCHEMBL20122717

SCHEMBL20122717

COc1ccc(-c2cc(C(=O)O)cc3c2[nH]c2c(C)nccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.51
MAOA P21397 3/20 0.50
ACHE P22303 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.50
DYRK3 O43781 1/20 0.50
CCNT1 O60563 1/20 0.50
CCNB2 O95067 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CDK1 P06493 1/20 0.50
CYP3A4 P08684 1/20 0.50
ADRA2A P08913 1/20 0.50
CYP2D6 P10635 1/20 0.50
CCNB1 P14635 1/20 0.50
HPGD P15428 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
CCNA2 P20248 1/20 0.50
SLC6A2 P23975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31714573 1.00 DYRK1A (0.51) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL20122816 0.90 DYRK1A (0.49) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL29756359 0.90 DYRK1A (0.49) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL20122962 0.83 MAOA (0.56) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL20122797 0.81 MAOA (0.54) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL29756413 0.81 MAOA (0.54) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL20122918 0.81 MAOA (0.54) DYRK1AMAOAACHESMN1; SMN2KDM4E
SCHEMBL29756312 0.81 MAOA (0.54) DYRK1AMAOAACHESMN1; SMN2KDM4E
Trifluoroacetic Acid SCHEMBL28811318 0.79 DYRK1A (0.43) DYRK1AMAOAACHESMN1; SMN2KDM4E
Trifluoroacetic Acid SCHEMBL29756370 0.79 DYRK1A (0.43) DYRK1AMAOAACHESMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885MAOA 245/4885ACHE 2558/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885MAOA 245/4885ACHE 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.